CA3073794A1 - Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family - Google Patents
Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family Download PDFInfo
- Publication number
- CA3073794A1 CA3073794A1 CA3073794A CA3073794A CA3073794A1 CA 3073794 A1 CA3073794 A1 CA 3073794A1 CA 3073794 A CA3073794 A CA 3073794A CA 3073794 A CA3073794 A CA 3073794A CA 3073794 A1 CA3073794 A1 CA 3073794A1
- Authority
- CA
- Canada
- Prior art keywords
- compound according
- mmol
- mixture
- heteroaryl
- lcms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
- C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
- C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
- C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D285/24—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with oxygen atoms directly attached to the ring sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1713962.7A GB201713962D0 (en) | 2017-08-31 | 2017-08-31 | Compounds |
| GB1713962.7 | 2017-08-31 | ||
| PCT/EP2018/073431 WO2019043139A1 (en) | 2017-08-31 | 2018-08-31 | FUSED [1,2,4] THIADIAZINE DERIVATIVES AS KAT INHIBITORS OF THE MYST FAMILY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3073794A1 true CA3073794A1 (en) | 2019-03-07 |
Family
ID=60050736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3073794A Abandoned CA3073794A1 (en) | 2017-08-31 | 2018-08-31 | Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210380548A1 (https=) |
| EP (1) | EP3676266A1 (https=) |
| JP (1) | JP6975860B2 (https=) |
| CA (1) | CA3073794A1 (https=) |
| GB (1) | GB201713962D0 (https=) |
| WO (1) | WO2019043139A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112028850B (zh) * | 2019-06-03 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种帕瑞昔布钠的中间体化合物 |
| CN112028851B (zh) * | 2019-06-03 | 2023-05-02 | 鲁南制药集团股份有限公司 | 一种帕瑞昔布钠中间体化合物 |
| WO2021030278A1 (en) * | 2019-08-12 | 2021-02-18 | Aligos Therapeutics, Inc. | Bicyclic compounds |
| TW202216131A (zh) | 2020-07-15 | 2022-05-01 | 美商輝瑞大藥廠 | 用於癌症治療之ｋａｔ６抑制劑方法及組合 |
| US20250145637A1 (en) | 2021-08-10 | 2025-05-08 | Jiangsu Hengrui Pharmaceuticals Co. Ltd. | Sulfonamide derivative, preparation method therefor and medical use thereof |
| WO2024023703A1 (en) | 2022-07-29 | 2024-02-01 | Pfizer Inc. | Dosing regimens comprising a kat6 inhibitor for the treatment of cancer |
| AU2024217108A1 (en) | 2023-02-10 | 2025-09-18 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Crystalline form of sulfonamide derivative and preparation method therefor |
| EP4689660A1 (en) | 2023-03-30 | 2026-02-11 | Pfizer Inc. | Kat6a as a predictive biomarker for treatment with a kat6a inhibitor and methods of treatment thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0938477A4 (en) * | 1996-11-13 | 1999-12-29 | Cephalon Inc | BENZOTHIAZOLO AND RELATED HETEROCYCLIC GROUPS CONTAINING CYSTEIN AND SERINE PROTEASE INHIBITORS |
| DE102005055355A1 (de) * | 2005-11-21 | 2007-10-31 | Merck Patent Gmbh | 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate |
| GB201510019D0 (en) * | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
-
2017
- 2017-08-31 GB GBGB1713962.7A patent/GB201713962D0/en not_active Ceased
-
2018
- 2018-08-31 JP JP2020533357A patent/JP6975860B2/ja not_active Expired - Fee Related
- 2018-08-31 EP EP18762297.2A patent/EP3676266A1/en not_active Withdrawn
- 2018-08-31 CA CA3073794A patent/CA3073794A1/en not_active Abandoned
- 2018-08-31 US US16/642,290 patent/US20210380548A1/en not_active Abandoned
- 2018-08-31 WO PCT/EP2018/073431 patent/WO2019043139A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019043139A1 (en) | 2019-03-07 |
| GB201713962D0 (en) | 2017-10-18 |
| JP2020531593A (ja) | 2020-11-05 |
| JP6975860B2 (ja) | 2021-12-01 |
| EP3676266A1 (en) | 2020-07-08 |
| US20210380548A1 (en) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7692095B2 (ja) | 化合物 | |
| CA3073794A1 (en) | Fused [1,2,4]thiadiazine derivatives which act as kat inhibitors of the myst family | |
| ES2855135T3 (es) | Amidas heterocíclicas como inhibidores de quinasa | |
| EP3189048B1 (en) | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors | |
| AU2017226004B2 (en) | Inhibitors of WDR5 protein-protein binding | |
| AU2005260056B2 (en) | Fused heterocyclic kinase inhibitors | |
| US10494376B2 (en) | Tetrahydroisoquinoline derived PRMT5-inhibitors | |
| JP2016509048A (ja) | アスパラギンメチル転移酵素の阻害剤としての２−（ヘテロ）アリールベンゾイミダゾール及びイミダゾピリジン誘導体 | |
| EP3423437A1 (en) | Inhibitors of wdr5 protein-protein binding | |
| WO2020002587A1 (en) | Compounds | |
| JP2019001715A (ja) | 三環性化合物 | |
| RU2838187C2 (ru) | Соединения | |
| WO2026015873A1 (en) | Stat6 inhibitors and uses thereof | |
| HK40041637A (en) | Compounds | |
| HK40041637B (en) | Compounds | |
| OA19881A (en) | Compounds. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20240228 |